Drug Overview

Quisinostat (also known as JNJ-26481585) is an innovative, high-potency “Smart Drug” designed to treat specific types of cancer by changing the way DNA is managed inside cells. It belongs to a modern class of medications known as Targeted Therapy. Unlike standard chemotherapy that kills all fast-growing cells, Quisinostat focuses on the biological switches that tell cancer cells to grow, hide, or die.

In clinical settings, Quisinostat is recognized for its ability to target the “epigenetic” landscape of a tumor. This means it doesn’t change the DNA itself, but it changes how the cell reads the DNA instructions. By resetting these instructions, Quisinostat can “wake up” the body’s natural ability to fight tumors. It is currently utilized in advanced clinical research across global oncology centers to treat both blood cancers and solid tumors.

Generic Name: Quisinostat (as Quisinostat hydrochloride)
US Brand Names: None (Currently an investigational drug)
Drug Class: Second-generation Histone Deacetylase (HDAC) Inhibitor
Route of Administration: Oral (Tablet) or Intravenous (IV) Infusion
FDA Approval Status: Investigational (Currently in Phase II Clinical Trials)

What Is It and How Does It Work? (Mechanism of Action)

To understand how Quisinostat works, imagine the DNA in your cells is like a long thread wrapped around spools called histones. If the thread is wrapped too tightly, the cell cannot read the “stop growing” instructions. If it is wrapped loosely, those instructions are easy to read.

At the molecular level, Quisinostat functions through a precise biochemical process:

HDAC Inhibition: Quisinostat binds to enzymes called Histone Deacetylases (HDACs), specifically Class I and II. These enzymes are the “cleaners” that wrap the DNA thread tightly around the spools.
Hyperacetylation: By blocking these enzymes, Quisinostat allows a chemical tag called an “acetyl group” to stay on the histones. This keeps the DNA thread loosely wrapped.
Gene Re-activation: Because the DNA is now “open,” the cell can finally read its Tumor Suppressor Genes. These are the natural instructions that tell a cell to stop dividing or to undergo apoptosis (programmed cell death).
Anti-Angiogenesis: Quisinostat also blocks the signals (like VEGF) that tumors use to grow new blood vessels. This effectively starves the tumor of the nutrients it needs to expand.

Because cancer cells rely heavily on these “cleaning” enzymes to stay aggressive, they are much more sensitive to Quisinostat than healthy cells.

FDA-Approved Clinical Indications

As an investigational drug, Quisinostat is not yet approved by the FDA for general sale. It is currently available to patients participating in registered clinical trials.

Oncological Uses (Investigational)

Ovarian Cancer: Studied in combination with chemotherapy for platinum-resistant cases.
Cutaneous T-cell Lymphoma (CTCL): Used for patients who have not responded to standard skin-directed therapies.
Multiple Myeloma: Investigated for use in patients with relapsed blood cancer.
Solid Tumors: Research includes lung, breast, and colorectal cancers.

Non-Oncological Uses

There are currently no non-oncological uses for this medication.

Dosage and Administration Protocols

Quisinostat is being tested in various schedules to find the best balance between killing cancer and keeping patients comfortable.

Parameter	Standard Investigational Protocol
Oral Dosage	6 mg to 12 mg (based on trial phase)
Frequency	Three times per week (e.g., Monday, Wednesday, Friday)
IV Administration	Calculated by body surface area (mg/m^2)
Cycle Length	21-day cycles (2 weeks on, 1 week off)

Dose Adjustments:

Hepatic (Liver) Insufficiency: Since the liver processes this drug, patients with liver issues usually receive a 25% to 50% lower starting dose.
Renal (Kidney) Insufficiency: No specific adjustments are currently required for mild kidney issues, but patients are monitored for electrolyte changes.

Clinical Efficacy and Research Results

Recent clinical data (2020–2025) highlights Quisinostat’s potential when used as part of a “Combination Therapy.”

Ovarian Cancer Success: In Phase Ib/II trials, the combination of Quisinostat and Paclitaxel/Carboplatin showed an Objective Response Rate (ORR) of approximately 25% to 30% in patients whose cancer had returned after previous treatment.
Lymphoma Response: Patients with Cutaneous T-cell Lymphoma experienced a significant reduction in skin itching and tumor thickness, with some maintaining “Stable Disease” for over 6 months.
Survival Impact: Numerical data from 2024 updates suggest that Quisinostat may extend Progression-Free Survival (PFS) by several months when added to standard chemotherapy regimens, compared to chemotherapy alone.

Safety Profile and Side Effects

Black Box Warning:

None. (As an investigational drug, it has not yet received a formal Black Box Warning).

Common Side Effects (>10%)

Fatigue: Feeling unusually tired or weak.
Nausea and Diarrhea: General stomach upset (manageable with common medications).
Thrombocytopenia: A drop in blood platelets, which may cause bruising.
Decreased Appetite: Leading to temporary weight loss.

Serious Adverse Events

Cardiac Arrhythmia: Changes in the heart’s electrical rhythm (QT prolongation).
Severe Myelosuppression: A significant drop in white blood cells, increasing infection risk.
Dehydration: Due to severe gastrointestinal symptoms.

Management Strategies

Heart Monitoring: Patients often receive an EKG (heart tracing) before and during treatment.
Supportive Care: Doctors prescribe “anti-emetics” (for nausea) and “growth factors” (to boost blood counts) as needed.

Research Areas

Quisinostat is a major subject of interest in Immunotherapy and Stem Cell Research. Scientists are exploring if Quisinostat can “prime” a tumor to be more visible to the immune system. By loosening the DNA, the drug might force cancer cells to show “hidden” markers on their surface that T-cells can find and attack. In the field of Regenerative Medicine, research is looking at how Quisinostat might affect the behavior of Cancer Stem Cells, the “mother cells” that often survive traditional chemotherapy and cause the cancer to return.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed

Baseline EKG: To check your heart’s electrical rhythm.
Complete Blood Count (CBC): To check white cells, red cells, and platelets.
Comprehensive Metabolic Panel (CMP): To ensure liver and kidney health.

Precautions During Treatment

Heart Health: Report any feeling of a “racing heart,” dizziness, or fainting immediately.
Infection Control: Wash hands frequently and avoid large crowds if your white blood cell count is low.

“Do’s and Don’ts” List

Do take your oral tablets at the same time each day on your “on” days.
Do drink 8 to 10 glasses of water daily to protect your kidneys.
Don’t take any new over-the-counter supplements without asking your oncologist, especially those that affect heart rhythm.
Don’t skip your blood test appointments; they are the only way to catch side effects before they become serious.

Legal Disclaimer

Standard medical information disclaimer: This guide is for informational purposes only and does not constitute medical advice. Quisinostat is an investigational drug and is only available through clinical trials. Always consult with a licensed oncologist or healthcare professional to discuss treatment options, risks, and benefits specific to your medical history. This content reflects clinical data available as of early 2026.